News
 Back
Fibrinogen EDQM Certificate of Suitability Granted - July 2010 Bovogen Biologicals is pleased to announce it has received European Directorate of Quality Medicines (EDQM) certification for its purified bovine fibrinogen. This will now enable customers to use this highly purified protein for medicinal applications.
To the company's knowledge, no other fibrinogen manufacturer globally has attained EDQM certification for this product......Read More
Australian Origin Trypsin Powder Now Available - June 2010 Bovogen Biologicals Pty Ltd is now manufacturing a high quality 1:250 lyophilized Trypsin sourced from Australian origin porcine pancreas glands.
Both Standard and Premium Cell Culture Grades of Trypsin powder are available as stock formats.
In addition, Bovogen Biologicals is able to offer variant Porcine or Bovine Trypsin products to agreed customer specifications.
For more information on Trypsin............. click here
For more information on Our Products............click here
Interpath Services appointed as Australian distributor for Bovogen Biologicals - March 2010 Bovogen Biologicals are pleased to announce that they have appointed Interpath Services Pty Ltd as their exclusive Australian distributor.
Interpath Services Pty Ltd is a highly regarded Australian supplier. Established in 1989, they offer a team of experienced and commited professionals who excel in the service that they provide to their customers.
We are very much looking forward to working together in the Australian market and have every confidence that our partnership will be of great benefit to our customers.
For more information on Foetal Bovine Serum (FBS)..............click here
For more information on Our Products....................................click here
Foetal Bovine Serum EDQM Certificate of Suitability Granted - August 2008
Bovogen Biologicals received a Certificate of Suitability from the European Directorate of Quality Medicines for it's range of Australian origin foetal bovine serum (FBS) products in June, 2008. This certification meets the criteria described in the current version of the monograph "Products with Risk of Transmitting Agents of Animal Spongiform Encephalopathies No. 1483 of the European Pharmacopoeia.
This Certificate of Suitability now enables Bovogen Biologicals foetal bovine serum to be used for the manufacture of medicines in the European Union. This certification compliments company's existing EDQM certification for its range of bovine serum albumin (BSA) products manufactured in Australia using raw materials of Australian origin only.
For more information on foetal bovine serum (FBS).......click here
Bovine fibrinogen product launched - December, 2006 Bovogen Biologicals completed a series of process trials for the extraction and purification of bovine fibrinogen from bovine blood serum. Large scale production was subsequently initiated and a fibrinogen product with excellent solubility, stability, high clotting properties was commecially available in December, 2006.
EDQM Certificate of Suitability granted – May, 2006 Bovogen Biologicals received a Certificate of Suitability from the European Directorate of Quality Medicines for it's range of bovine serum albumin products in May, 2006. This certification meets the criteria described in the current version of the monograph "Products with Risk of Transmitting Agents of Animal Spongiform Encephalopathies No. 1483 of the European Pharmacopoeia.
This Certificate of Suitability also covers some of the components used in the manufacture of at least one type of BSA product manufactured by Bovogen Biologicals.
Bovogen Biologicals receives Industry Award – May, 2006 Bovogen Biologicals received an Australian Red Meat Industry Award for Innovation following nomination and selection from a number of Australian bioactives manufacturers by an independant industry panel. The award was for the development of a novel bovine serum albumin product called 'BovoLep' which has been shown by industry to enhance the growth of fastidious micro-organisms such as Leptospira. BovoLep BSA has also been shown to be a superior product to other BSAs when used as a supplement in serum free mammalian cell culture systems.
Managing Director, Rick Clements, accepted the award on behalf of Bovogen Biologicals at the Australian Red Meat Industry conference dinner in Rockhampton, Queensland in May, 2006.
Biovine Biologicals formed - 2005 Managing Director of Bovogen Biologicals, Rick Clements teams up with Dr. David Kennedy from Biotechnology Development Ltd. to form and register a new company called Biovine Biologicals Pty Ltd.
Biovine Biologicals shall focus on the development and supply of ovine proteins and related products for the life science industries. Australia is one of a relative few countries that is scrapie free (ovine form of a transmissable spongiform encephalopathy) hence, making the country an excellent source of ovine biological products. Australia's abundant sheep herds also facilitates the sourcing of inexpensive raw materials.
Certain ovine blood clotting proteins shall also be developed and manufactured by Bovogen Biologicals on behalf of Biovine Biologicals for the development of haemostasis applications by international collaborators.
Biovine Biologicals' ovine based products shall also provide an alternative to traditional bovine sourced compounds hence, providing global life science industries with products that are not affected by BSE concerns.
EU and Taiwan blood products listing granted – November, 2005 Bovogen Biologicals is granted blood products export listing for the EU and Taiwan by the Australian Quarantine Inspection Service (AQIS). This enables the company to export blood products to these destinations following audit and approval by AQIS.
Foetal bovine serum (FBS) production commences – August, 2005 Bovogen Biologicals has added foetal bovine serum (FBS) to it's product portfolio. Using only Australian sourced foetal bovine blood, the company commenced manufacture of an FBS product of exceptional quality which has been promoted both domestically and internationally by Bovogen's network of distributors and agents.
BovoLep BSA production commences – Mid, 2004 Through market research, Bovogen Biologicals discovered that animal pharmaceutical manufacturers using BSA for the growth of a variety of micro-organism derived vaccines were constantly frustrated at the variability in the performance of cultures. Through development work with industry partners and customers, Bovogen developed a non-animal, synthetic lipid fortified BSA product that demonstated advantages such as process and yield consistency, enhanced product yield and lipid content consistency.
BovoLep BSA was also shown to be a far superior product in serum free mammalian culture systems when compared to traditional BSA products.
As a result of this collaboratoive effort, Bovogen commenced production of BovoLep BSA in mid-2004.
Large scale BSA production begins – Late 2003 Bovogen Biologicals commenced large scale BSA production in the last quarter of 2003 following the completion of commissioning and validation of it's manufacturing facility.
BSA production trials commence – 2002 Bovogen Biologicals commenced pilot phase trials of it's BSA manufacturing process during the course of 2002. Process parameters were developed, process control systems were implemented and large scale facility design was initiated.
|
Top